Business
Aytu is a prescription-pharma company focused on EXXUA commercialization, ADHD products, and pediatric prescription products.
Aytu revenue grew slightly and losses narrowed, but cash burn worsened, equity fell, and Altman-Z stayed in distress.
The read at a glance✓ Audited against SEC data
- Business mix — Prescription CNS and pediatric productsNote
- Revenue — Revenue rose 1.8%OK
- Losses — Net loss narrowed to $13.6MOK
- Cash — Free cash flow worsened to -$2.2MWatch
- Balance sheet — Equity fell 31.6%Watch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Altman-Z distress; other screens safeWatch
Where the revenue comes from
Fiscal 2025, as AYTU BIOPHARMA, INC reports it. History and quarterly detail are in the app.
- ADHD Portfolio$57.6M
- The Pediatric Portfolio$8.8M
- Product and Service, Other$37K
Leadership changes
From AYTU BIOPHARMA, INC's own filings, the day they're filed.
- Christopher Brooke · Chief Operating Officer · departureeff. 2023-10-13
Latest filings
- 8-K · Company announcement2026-06-25
- 8-K · Company announcement2026-05-13
- 10-Q · Quarterly report2026-05-13
- 8-K · Company announcement2026-04-02
- 8-K · Company announcement2026-02-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AYTU BIOPHARMA, INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.